Back to top

LACOG 0211 – ALK

  /    /  LACOG 0211 – ALK

A clinical and epidemiologic study of EML4-ALK and other ALK fusions genes in lung cancer patients in Latin America.

Type of Study: Clinical Trial

Sponsor / Support: LACOG, Instituto Nacional de Câncer (INCA), Pfizer

Primary Objectives: To estimate the prevalence of EML4-ALK fusio gene in Latin American in patients with non squamous-cell lung carcinoma.

Design: Retrospective study

Sample Size: 1154 patients

Principal Investigator: Carlos Gil, Clarissa Baldotto, Carlos Barrios

Countries LATAM: Argentina, Brazil, Peru, Colombia and Mexico